5-Hydroxymethylcytosines in circulating cell-free DNA reveal a diagnostic biomarker for glioma. Issue 10 (October 2022)

• Record Type: Journal Article
• Authors: Zhang, Chunyu; Zhou, Wei; Tan, Yinqiu; Tian, Daofeng; Zhong, Chunlong
• Is Part Of: Heliyon. Volume 8:Issue 10(2022)
• Publication Date: 2022-10
• Subjects: Diagnostic biomarker -- cfDNA -- 5 hm C -- Glioma -- LASSO; Research -- Periodicals; Medical sciences -- Periodicals; Natural history -- Periodicals; Social sciences -- Periodicals; Earth sciences -- Periodicals; Physical sciences -- Periodicals; 507.2
• DOI: 10.1016/j.heliyon.2022.e11022
• Languages: English
• ISSNs: 2405-8440

Abstract

Abstract: Gliomas typically have unfavorable prognosis, due to late detection and interventions. However, effective biomarkers for early glioma diagnosis based on 5-hydroxymethylcytosines (5 hm C) in circulating cell-free DNA (cfDNA) are not currently available. 5 hm C profiles in GSE132118 set were subjected for establishment of diagnostic model using the LASSO (least absolute shrinkage and selection operator) algorithm. The 5 hm C-based models demonstrated great potency in differentiating healthy subjects from gliomas, with area under the curves (AUCs) > 0.91 in the training and validation sets. Moreover, the indicator performed well in combination with clinicopathological characteristics to differentiate glioblastomas (GBMs) from lower grade glioma (LGGs). Enrichment analysis on 5 hm C profiles displayed great correlation with glioma pathophysiology. The 5 hm C-derived biomarker might act as an effective and non-invasive measure in glioma screening. Abstract : Diagnostic biomarker; cfDNA, 5 hm C; Glioma; LASSO.